I 
113TH CONGRESS 
2D SESSION 
H. R. 4709 
To improve enforcement efforts related to prescription drug diversion and 
abuse, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 21, 2014 
Mr. MARINO (for himself, Mrs. BLACKBURN, Mr. WELCH, and Ms. CHU) in-
troduced the following bill; which was referred to the Committee on En-
ergy and Commerce, and in addition to the Committee on the Judiciary, 
for a period to be subsequently determined by the Speaker, in each case 
for consideration of such provisions as fall within the jurisdiction of the 
committee concerned 
A BILL 
To improve enforcement efforts related to prescription drug 
diversion and abuse, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Ensuring Patient Ac-
cess and Effective Drug Enforcement Act of 2014’’. 
SEC. 2. REGISTRATION PROCESS UNDER CONTROLLED 
SUBSTANCES ACT. 
(a) DEFINITIONS.— 
VerDate Mar 15 2010 
20:59 May 22, 2014
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4709.IH
H4709
TKELLEY on DSK3SPTVN1PROD with BILLS
(1) CONSISTENT
WITH
THE
PUBLIC
HEALTH 
AND SAFETY.—Section 303 of the Controlled Sub-
stances Act (21 U.S.C. 823) is amended by adding 
at the end the following: 
‘‘(j) In this section, the phrase ‘consistent with the 
public health and safety’ means having a substantial rela-
tionship to this Act’s purpose of preventing diversion and 
abuse of controlled substances.’’. 
(2) IMMINENT DANGER.—Section 304(d) of the 
Controlled Substances Act (21 U.S.C. 824(d)) is 
amended— 
(A) by striking ‘‘(d) The Attorney Gen-
eral’’ and inserting ‘‘(d)(1) The Attorney Gen-
eral’’; and 
(B) by adding at the end the following: 
‘‘(2) In this subsection, the term ‘imminent danger’ 
means a significant and present risk of death or serious 
bodily harm that is more likely than not to occur in the 
absence of an immediate suspension order.’’. 
(b) OPPORTUNITY TO SUBMIT CORRECTIVE ACTION 
PLAN PRIOR TO REVOCATION OR SUSPENSION.—Section 
304(c) of the Controlled Substances Act (21 U.S.C. 
824(c)) is amended— 
(1) by striking ‘‘(c) Before’’ and inserting 
‘‘(c)(1) Before’’; and 
VerDate Mar 15 2010 
20:59 May 22, 2014
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4709.IH
H4709
TKELLEY on DSK3SPTVN1PROD with BILLS
(2) by adding at the end the following: 
‘‘(2) Before revoking or suspending a registration 
pursuant to section 303, the Attorney General shall— 
‘‘(A) provide— 
‘‘(i) notice to the registrant of the grounds 
for revocation or suspension; and 
‘‘(ii) in the case of any such grounds con-
sisting of a violation of law, a specific citation 
to such law; 
‘‘(B) give the registrant an opportunity to sub-
mit a corrective action plan within a reasonable pe-
riod of time to demonstrate how the registrant plans 
to correct the grounds for revocation or suspension; 
and 
‘‘(C) determine whether— 
‘‘(i) in light of the plan, revocation or sus-
pension proceedings should be discontinued or 
deferred; or 
‘‘(ii) additional changes need to be made in 
the corrective action plan.’’. 
SEC. 3. REPORT TO CONGRESS ON EFFECTS OF LAW EN-
FORCEMENT ACTIVITIES ON PATIENT AC-
CESS TO MEDICATIONS. 
(a) IN GENERAL.—Not later than one year after the 
date of enactment of this Act, the Secretary of Health and 
VerDate Mar 15 2010 
20:59 May 22, 2014
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4709.IH
H4709
TKELLEY on DSK3SPTVN1PROD with BILLS
Human Services, acting through the Commissioner of 
Food and Drugs and the Director of the Centers for Dis-
ease Control and Prevention, and in consultation with the 
Administrator of the Drug Enforcement Administration 
and the Director of National Drug Control Policy, shall 
submit a report to the Congress— 
(1) assessing how patient access to medications 
could be adversely impacted by Federal and State 
law enforcement activities; and 
(2) identifying how collaboration between agen-
cies and stakeholders can benefit patients and pre-
vent diversion and abuse of controlled substances. 
(b) CONSULTATION.—The report under subsection 
(a) shall incorporate feedback and recommendations from 
the following: 
(1) Patient groups. 
(2) Pharmacies. 
(3) Manufacturers of drugs. 
(4) Common or contract carriers and ware-
housemen. 
(5) Hospitals, physicians, and other health care 
providers. 
(6) State attorneys general. 
(7) Law enforcement officials, including local 
law enforcement officials. 
VerDate Mar 15 2010 
20:59 May 22, 2014
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H4709.IH
H4709
TKELLEY on DSK3SPTVN1PROD with BILLS